ATE258797T1 - Verwendung von amifostin - Google Patents

Verwendung von amifostin

Info

Publication number
ATE258797T1
ATE258797T1 AT98906688T AT98906688T ATE258797T1 AT E258797 T1 ATE258797 T1 AT E258797T1 AT 98906688 T AT98906688 T AT 98906688T AT 98906688 T AT98906688 T AT 98906688T AT E258797 T1 ATE258797 T1 AT E258797T1
Authority
AT
Austria
Prior art keywords
compounds
aminoalkyl
amifostine
adverse
patients
Prior art date
Application number
AT98906688T
Other languages
English (en)
Inventor
Martin Stogniew
Philip S Schein
Original Assignee
Medimmune Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Oncology Inc filed Critical Medimmune Oncology Inc
Application granted granted Critical
Publication of ATE258797T1 publication Critical patent/ATE258797T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Insulating Materials (AREA)
AT98906688T 1997-02-12 1998-02-11 Verwendung von amifostin ATE258797T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/798,840 US6051563A (en) 1997-02-12 1997-02-12 Methods for the administration of amifostine and related compounds
PCT/US1998/003614 WO1998034622A1 (en) 1997-02-12 1998-02-11 Methods for the administration of amifostine

Publications (1)

Publication Number Publication Date
ATE258797T1 true ATE258797T1 (de) 2004-02-15

Family

ID=25174410

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906688T ATE258797T1 (de) 1997-02-12 1998-02-11 Verwendung von amifostin

Country Status (11)

Country Link
US (3) US6051563A (de)
EP (1) EP1007055B1 (de)
JP (1) JP2001512447A (de)
AT (1) ATE258797T1 (de)
AU (1) AU750591B2 (de)
CA (2) CA2280773C (de)
DE (1) DE69821498T2 (de)
DK (1) DK1007055T3 (de)
ES (1) ES2216271T3 (de)
PT (1) PT1007055E (de)
WO (1) WO1998034622A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds
US6573253B2 (en) * 1997-02-12 2003-06-03 Medimmune Oncology Inc. Methods for the administration of amifostine and related compounds
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6239119B1 (en) * 1998-04-27 2001-05-29 Medimmune Oncology, Inc. Topical administration of amifostine and related compounds
US6384259B1 (en) * 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
BR0110403A (pt) * 2000-04-26 2004-02-25 Univ Oregon Health Sciences Administração de um composto quimioprotetor baseado em tiol
US20040033267A1 (en) * 2002-03-20 2004-02-19 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7053072B2 (en) * 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
WO2006044738A2 (en) * 2004-10-18 2006-04-27 Maroon Biotech Corporation Methods and compositions for treatment of free radical injury
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
CN103336902B (zh) * 2013-06-27 2016-01-13 西安交通大学 一种基于模拟分布平衡血药浓度的药物绝对生物利用度检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892824A (en) * 1968-12-16 1975-07-01 Southern Res Inst S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates
AU636107B2 (en) * 1988-02-23 1993-04-22 U.S. Bioscience, Inc. Method for protection from chemotherapeutic side effects
SG47101A1 (en) 1992-07-31 1998-03-20 Us Bioscience Crystalline amifostine compositions and methods for the preparation and use of same
US5424471A (en) * 1992-07-31 1995-06-13 U.S. Bioscience, Inc. Crystalline amifostine compositions and methods of the preparation and use of same
ATE173627T1 (de) * 1992-09-04 1998-12-15 Fuji Chem Ind Co Ltd Medizinische zusammensetzung
DE69526395D1 (de) * 1994-08-13 2002-05-23 Roche Diagnostics Gmbh Verwendung von Interferon-gamma zur Vermeidung der Proliferation und Differenzierung der primitiven Hämapoietischen Vorläuferzellen
US5846958A (en) * 1995-02-17 1998-12-08 U.S. Bioscience, Inc. Methods of using aminothiols to promote hematopoietic progenitor cell growth
US6051563A (en) * 1997-02-12 2000-04-18 U.S. Bioscience, Inc. Methods for the administration of amifostine and related compounds

Also Published As

Publication number Publication date
DE69821498D1 (de) 2004-03-11
US6127351A (en) 2000-10-03
JP2001512447A (ja) 2001-08-21
EP1007055A1 (de) 2000-06-14
EP1007055B1 (de) 2004-02-04
AU6184998A (en) 1998-08-26
US6051563A (en) 2000-04-18
PT1007055E (pt) 2004-06-30
DK1007055T3 (da) 2004-06-07
ES2216271T3 (es) 2004-10-16
WO1998034622A1 (en) 1998-08-13
CA2280773A1 (en) 1998-08-13
EP1007055A4 (de) 2002-05-29
US6218377B1 (en) 2001-04-17
AU750591B2 (en) 2002-07-25
DE69821498T2 (de) 2004-12-02
CA2280773C (en) 2008-07-22
CA2625727A1 (en) 1998-08-13

Similar Documents

Publication Publication Date Title
ATE258797T1 (de) Verwendung von amifostin
KR900009079A (ko) 비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
NO20014415L (no) Medisinske preparater til behandling av &lt;alfa&gt;-galaktosidase- A-defisiens
DE69834658D1 (de) Verwendung von aminothiolverbindungen zur behandlung von nerven- und nieren-erkrankungen und der arzneimitteltoxizität
MXPA03003960A (es) Combinaciones de farmacos (v.gr., clorpromazina y pentamidina) para el tratamiento de desordenes neoplasticos.
DE69941586D1 (de) Verwendung von Uridin in Kombination mit Cholin zur Behandlung von Gedächtnisstörungen
NZ516349A (en) Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
SE9702860D0 (sv) New use
PT996460E (pt) Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6
ATE239474T1 (de) Verwendung von levobupivacain
DE69617729D1 (de) Verwendung von antimineralcorticoidverbindungen gegen das drogenentzugssyndrom
ATE372774T1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
TR200001288T2 (tr) Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler.
RS52011B (sr) Nova primena derivata taksoida
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
FI911788A0 (fi) Konjugater av difluorglutaminsyra med folater och antifolater foer behandling av neoplastiska sjukdomar.
DE69018099D1 (de) Polyamin-Derivate als antineoplastische Mittel.
TR199802200A2 (xx) S�lfonamid s�bstit�e edilmi� benzopiran t�revleri, �retilme y�ntemi.
MD1140B1 (en) Remedy possessing a regenerative and cytoprotective activity
BR9909867A (pt) Composições estáveis contendo levosimendan e ácido algìnico
TR200000728T2 (tr) Kronik hepatit C&#39; nin tedavisinde IFN-alfa ve amantadin kullanımı.
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
SE9003181D0 (sv) Use of heparin fraction
DK0458537T3 (da) Anvendelse af en terapeutisk forbindelse til behandling af bronkitis
AU2444695A (en) Use of intravenously administered iron in the therapy of tumoral and infectious diseases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007055

Country of ref document: EP